Company announcements · 17/11/20261 min read
Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer
Summary
HONG KONG, Nov. 16, 2026 — Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy for the...